SEC 13F Intelligence

Managers / Q4 2024 · view latest →

Krensavage Asset Management, LLC

CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582

Reported Value
$169M
Q4 2024
Positions
12
Filings on Record
32
2019–present window
Filed
Feb 18, 2025
amendment (RESTATEMENT)

Summary

Krensavage Asset Management, LLC reported $169M in U.S.-listed holdings across 12 positions for Q4 2024.

Its largest position, UTHR, represents 19.2% of the portfolio.

Compared with Q3 2024, the fund opened 0 new positions and exited 1.

Portfolio Metrics

Turnover
+4.0%
vs prior filed quarter
Top-10 Concentration
+98.8%
share of reported value
Largest Position
+19.2%
United Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $370MQ1 ’19Q2 ’19: $308MQ3 ’19: $260MQ4 ’19: $293MQ1 ’20: $311MQ1 ’20Q2 ’20: $368MQ3 ’20: $314MQ4 ’20: $342MQ1 ’21: $289MQ1 ’21Q2 ’21: $295MQ3 ’21: $319MQ4 ’21: $288MQ1 ’22: $290MQ1 ’22Q2 ’22: $302MQ3 ’22: $314MQ4 ’22: $324MQ1 ’23: $329MQ1 ’23Q2 ’23: $316MQ3 ’23: $272MQ4 ’23: $282MQ1 ’24: $226MQ1 ’24Q2 ’24: $218MQ3 ’24: $178MQ4 ’24: $169MQ1 ’25: $181MQ1 ’25Q2 ’25: $189MQ3 ’25: $235MQ4 ’25: $283MQ1 ’26: $256MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 82.8%ADR: 10.2%Other: 7.0%
  • Common Stock · 82.8% · $140M
  • ADR · 10.2% · $17M
  • Other · 7.0% · $12M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
REGNREGENERON PHARMACEUTICALSSOLD OUT−3530−$371,000$0
ENTAENANTA PHARMACEUTICALS INCADDED+619.3K2.12M−$3M$12M
INDIVIOR PLCADDED+233.8K935.7K+$5M$12M
EXELEXELIXIS INCTRIMMED−315.7K965.9K−$1M$32M
VNDAVANDA PHARMACEUTICALS INCTRIMMED−35.9K378.8K−$131,000$2M
UTHRUNITED THERAPEUTICS CORPTRIMMED−8.3K92.1K−$3M$32M
MURAL ONCOLOGY PLCTRIMMED−5.7K70.2K−$11,000$226,000
ALKSALKERMES PLCTRIMMED−13.4K238.1K−$190,000$7M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2024

12 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1UTHRUNITED THERAPEUTICS CORPhistory →COM19.22%$32M92.1K
2EXELEXELIXIS INChistory →COM19.03%$32M965.9K
3CAHCARDINAL HEALTH INChistory →COM14.61%$25M208.8K
4BIIBBIOGEN INChistory →COM9.85%$17M108.9K
5JAZZJAZZ PHARMACEUTICALS PLChistory →COM7.71%$13M105.8K
6ENTAENANTA PHARMACEUTICALS INChistory →COM7.20%$12M2.12M
7INDIVIOR PLCCOM6.88%$12M935.7K
8BNTXBIONTECH SE-ADRhistory →COM5.98%$10M88.7K
9SNYSANOFI-ADRhistory →COM4.26%$7M149.2K
10ALKSALKERMES PLChistory →COM4.05%$7M238.1K
11VNDAVANDA PHARMACEUTICALS INChistory →COM1.07%$2M378.8K
12MURAL ONCOLOGY PLCCOM0.13%$226,00070.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$256M20May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$283M18Feb 18, 202613F-HRchanges · EDGAR ↗
Q3 2025$235M17Nov 17, 202513F-HRchanges · EDGAR ↗
Q2 2025$189M15Aug 15, 202513F-HRchanges · EDGAR ↗
Q1 2025$181M14May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$169M12Feb 18, 2025RESTATEMENTchanges · EDGAR ↗
Q3 2024$178M13Nov 15, 202413F-HRchanges · EDGAR ↗
Q2 2024$218M13Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$226M12May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$282M12Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$272M12Nov 15, 202313F-HRchanges · EDGAR ↗
Q2 2023$316M12Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$329M12May 16, 202313F-HRchanges · EDGAR ↗
Q4 2022$324M12Feb 15, 202313F-HRchanges · EDGAR ↗
Q3 2022$314M14Nov 15, 202213F-HRchanges · EDGAR ↗
Q2 2022$302M14Aug 16, 202213F-HRchanges · EDGAR ↗
Q1 2022$290M13May 17, 202213F-HRchanges · EDGAR ↗
Q4 2021$288M10Feb 15, 202213F-HRchanges · EDGAR ↗
Q3 2021$319M13Nov 16, 202113F-HRchanges · EDGAR ↗
Q2 2021$295M13Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$289M12May 18, 202113F-HRchanges · EDGAR ↗
Q4 2020$342M12Feb 17, 202113F-HRchanges · EDGAR ↗
Q3 2020$314M11Dec 8, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$368M11Aug 20, 2020RESTATEMENTchanges · EDGAR ↗
Q1 2020$311M13May 18, 202013F-HRchanges · EDGAR ↗
Q4 2019$293M12Feb 18, 202013F-HRchanges · EDGAR ↗
Q3 2019$260M10Nov 15, 201913F-HRchanges · EDGAR ↗
Q2 2019$308M10Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$370M12May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.